Skip to main content
OpenTrials
Completed

NCT Number: NCT03769779

Evaluation of the Benefits of FloraGLO™ Lutein on Skin Health

Therefore, the present study is designed to contribute to the body of literature by investigating the effect of 12-weeks of lutein supplementation on multiple parameters of skin health and appearance in healthy women.

Completed

Looking for future studies?

Notify Me

Key information

Age range

30 year–65 year

Sex eligibility

Female

Study type

Interventional

Phase

Not applicable

Primary location

International Research Services, Inc.

Port Chester, New York, 10573, United States

About this study

This is a randomized, double-blind, placebo-controlled, parallel twelve-week study of the performance of an oral test product to evaluate the effects of twelve weeks of lutein supplementation on skin health and appearance in healthy women. A seven-day washout period will precede the evaluation period. The subjects in each cohort will use consume one softgel of their assigned test product (treatment or placebo) daily in the morning with breakfast for 12 weeks. Changes in skin condition and appearance as well as blood chemistry will be assessed using results from expert visual grading, instrumental assessments, skin and blood assays and subjective questionnaire responses. Subjects will be recruited during the winter season to account for seasonal variations of skin parameters.

Evaluation points will occur pre-application (Baseline; Week 0) and after 42 and 84 days of use (D42, D84; Week 6, Week 12). Data will be collected on the following outcomes:

  • Skin Hydration 2. Skin texture/smoothness 2. Reduction of facial fine lines and wrinkles 3. Skin elasticity and firmness 4. Sagging skin, dry skin, skin tone, appearance from expert clinical grading and subjective questionnaire responses.
  • Skin hydration 7. Skin collagen 8. Skin lipid content. 9. Skin Carotenoids

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Females in good health, and between the ages of 30 and 65 years old
  • Fitzpatrick Skin Type I-V
  • Mild to moderate loss of skin elasticity, wrinkles (global) and rough skin texture
  • Able to read, understand and sign an informed consent form
  • Willing and able to follow all study directions, attend study visits as scheduled and willing to accept the restrictions of the study
  • Willing and able to maintain regular diet, exercise, hydration, and sleep patterns throughout the study

Exclusion criteria

  • Participating in any other clinical study
  • Acute or chronic disease or medical condition
  • Unreliable or unlikely to be available for the duration of the study
  • Routine use of tanning bed(s)
  • History of abnormal response to sunshine
  • Current usage of medications with contraindication of enhancing sun exposure, or medications for skin conditions.
  • History of allergic reactions, skin sensitization and/or known allergies to cosmetic ingredients, toiletries, sunscreens, etc.
  • Immunocompromised subjects
  • Subject has a history of unconventional sleep patterns
  • Started Hormone Replacement Therapy within the last three months
  • Using oral contraception for less than three months
  • Known to be pregnant, lactating or planning to become pregnant within six months
  • Unable to communicate or cooperate with the Principal Investigator due to language problems, poor mental development, or impaired cerebral function

Treatment and study plan

FloraGLO Lutein

Dietary Supplement

Lutein (FloraGLO™) in safflower oil

Safflower oil

Dietary Supplement

Safflower Oil

Primary outcomes

  1. Objective Skin Hydration

    Time frame: ANOVA including weeks 6 and 12

    Corneometer Value

  2. Subjective Skin Hydration

    Time frame: ANOVA including weeks 6 and 12

    Subjective Questionnaire Visual Analog Scale

Secondary outcomes

  1. Objective Skin Texture

    Time frame: ANOVA including weeks 6 and 12

    Expert clinical grading

  2. Subjective Skin Texture

    Time frame: ANOVA including weeks 6 and 12

    Subjective Questionnaire Visual Analog Scale

  3. Objective Facial Lines and Wrinkles

    Time frame: ANOVA including weeks 6 and 12

    Expert clinical grading

  4. Subjective Facial Lines and Wrinkles

    Time frame: ANOVA including weeks 6 and 12

    Subjective Questionnaire Visual Analog Scale

  5. Objective Sagging skin, dry skin, skin tone, and overall appearance

    Time frame: ANOVA including weeks 6 and 12

    Expert clinical grading

  6. Subjective Sagging skin, dry skin, skin tone, and overall appearance

    Time frame: ANOVA including weeks 6 and 12

    Subjective Questionnaire Visual Analog Scale

  7. Objective Skin elasticity

    Time frame: ANOVA including weeks 6 and 12

    Expert clinical grading

  8. Subjective Skin elasticity

    Time frame: ANOVA including weeks 6 and 12

    Subjective Questionnaire Visual Analog Scale

  9. Skin Collagen Ultrasound

    Time frame: ANOVA including weeks 6 and 12

    Ultrasound

  10. Skin Collagen SIAsScope

    Time frame: ANOVA including weeks 6 and 12

    SIAsScope assessments

  11. Skin Lipids

    Time frame: ANOVA including weeks 6 and 12

    HPLC of tape strips

  12. Skin Carotenoids

    Time frame: ANOVA including weeks 6 and 12

    Total carotenoid concentration

Sponsors and collaborators

Lead sponsor

Kemin Foods LC

Industry

Registry information

Official study title

A 12-Week, Randomized, Double-Blind, Placebo-Controlled Evaluation of the Benefits of FloraGLO™ Lutein on Skin Health

Important dates

Study start
2019
Primary completion
2019
Study completion
2020
First posted
Dec 10, 2018
Registry last updated
Feb 3, 2021

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.